Standard first-line antibiotic therapy for acute tonsillitis relies on beta-lactam agents. When a patient has a confirmed allergy to penicillin or beta-lactam antibiotics, that entire drug class must be excluded, and the treatment approach shifts accordingly.
Clinical ScenarioThis protocol applies to patients presenting with acute tonsillitis who have a confirmed allergy to penicillin or beta-lactam antibiotics. The allergy status rules out first-line beta-lactam options, requiring a structured alternative approach from the outset.
In this setting, treatment draws on antibiotic classes that do not share the beta-lactam structure — specifically macrolides and lincosamides, which are considered the treatment of choice when beta-lactam allergy is confirmed. The full protocol specifies which agents within these classes are preferred and why, based on current resistance patterns.
Macrolides and lincosamides (clindamycin) are considered the treatment of choice in patients who are allergic, or suspected to be allergic, to beta-lactam antibiotics.
If there is confirmed allergy to penicillin, it is advised that clindamycin or a 16-atom macrolide such as josamycin is used, since GABHS resistance, although it has decreased in recent years, remains greater to 14 and 15-atom macrolides than to 16-atom macrolides.
DOI: 10.1016/j.otoeng.2015.05.003
View source ↗